Esperion Therapeutics reported a strong Q3 2025 with a 69% year-over-year revenue increase, leveraging strategic investments and marketing efforts to drive prescription growth amid heightened recognition of its bempedoic acid products.

• Total revenue reached $87.3 million, driven by a 31% year-over-year growth in U.S. net product revenue.
• The company secured agreements with four generic manufacturers to protect its NEXLETOL franchise through April 2040, enhancing long-term value.
• Increased prescriber engagement and strategic marketing aimed at statin-intolerant patients contributed to improved brand awareness and prescription growth.
• The introduction of bempedoic acid products in ESC/EAS guidelines marks a significant clinical validation, with expectations for U.S. guideline inclusion in early 2026.
• An 87% average approval rate for Medicare coverage reflects successful efforts in enhancing patient access.